FDA Determines Regulatory Review Period for NUPLAZID Patent Extension

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of NUPLAZID, a human drug product, following the submission of applications to the U.S. Patent and Trademark Office (USPTO). This determination is being published as required by law.